Chimerix Inc (CMRX)
0.8924
-0.01
(-1.23%)
USD |
NASDAQ |
Sep 27, 16:00
0.8722
-0.02
(-2.26%)
After-Hours: 20:00
Chimerix SG&A Expense (Annual): 24.60M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.60M |
| December 31, 2022 | 22.13M |
| December 31, 2021 | 18.67M |
| December 31, 2020 | 13.66M |
| December 31, 2019 | 21.17M |
| December 31, 2018 | 23.58M |
| December 31, 2017 | 27.15M |
| Date | Value |
|---|---|
| December 31, 2016 | 25.01M |
| December 31, 2015 | 31.30M |
| December 31, 2014 | 17.53M |
| December 31, 2013 | 8.327M |
| December 31, 2012 | 6.397M |
| December 31, 2011 | 6.985M |
| December 31, 2010 | 7.606M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
13.66M
Minimum
2020
24.60M
Maximum
2023
20.05M
Average
21.17M
Median
2019
SG&A Expense (Annual) Benchmarks
| SIGA Technologies Inc | 22.04M |
| Abbott Laboratories | 10.95B |
| Emergent BioSolutions Inc | 368.40M |
| Tonix Pharmaceuticals Holding Corp | 34.75M |
| Geovax Labs Inc | 6.022M |